<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Rifamycins: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int199-rifamycins.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int199-rifamycins.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int199-rifamycins.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a> &gt; <a href="bnf_int127-antibacterials.htm">Antibacterials</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int198-ofloxacin.htm" title="Previous: Ofloxacin">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int200-rifabutin.htm" title="Next: Rifabutin">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Rifamycins</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Rifamycins</strong> has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Interactions do not apply to rifaximin</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td><p><span></span> <span>rifamycins</span> <span>reduce plasma concentration of</span> <span>clarithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>corticosteroids</span> <span>(reduced effect)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>coumarins</span> <span>(reduced anticoagulant effect)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int161-dapsone.htm">Dapsone</a></td><td><p><span></span> <span>rifamycins</span> <span>reduce plasma concentration of</span> <span>dapsone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>disopyramide</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>oestrogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>phenytoin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>progestogens</span> <span>(reduced contraceptive effect—see <a title="target-block: COCs interactions" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int268-sulfonylureas.htm">Sulfonylureas</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>possibly accelerate metabolism of</span> <span>sulfonylureas</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int275-tolbutamide.htm">Tolbutamide</a></td><td class="cAI"><p><span></span> <span>rifamycins</span> <span>accelerate metabolism of</span> <span>tolbutamide</span> <span>(reduced effect)</span>  </p></td><td></td></tr></tbody></table><p><strong>Rifamycins</strong> belongs to <strong>Antibacterials</strong> and will have the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1058-typhoid-vaccine-oral.htm">Typhoid Vaccine (oral)</a></td><td><p><span></span> <span>antibacterials</span> <span>inactivate</span> <span>oral typhoid vaccine</span> <span>—see under Typhoid vaccines, <a title="monograph-family: Typhoid vaccines" href="PHP8409-typhoid-vaccines.htm">section 14.4</a></span>  </p></td><td></td></tr></tbody></table><p><strong>Rifabutin</strong> belongs to <strong>Rifamycins</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int300-antifungals-triazole.htm">Antifungals, Triazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>possibly increased by</span> <span>triazoles</span> <span>(increased risk of uveitis—reduce <span>rifabutin</span> dose)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>rifabutin</span> <span>possibly reduces plasma concentration of</span> <span>aripiprazole</span> <span>—increase dose of <span>aripiprazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>atazanavir</span> <span>(reduce dose of <span>rifabutin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int431-atovaquone.htm">Atovaquone</a></td><td><p><span>avoidance of concomitant </span> <span>rifabutin</span> <span>advised by manufacturer of</span> <span>atovaquone</span> <span>(plasma concentration of both drugs reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int167-azithromycin.htm">Azithromycin</a></td><td class="cAI"><p><span>increased risk of side-effects including neutropenia when </span> <span>rifabutin</span> <span>given with</span> <span>azithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span> <span>rifabutin</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>rifabutin</span> <span>reduces plasma concentration of</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>plasma concentration of  </span> <span>rifabutin</span> <span>increased by</span> <span>clarithromycin</span> <span>(increased risk of toxicity—reduce <span>rifabutin</span> dose)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>darunavir</span> <span>(reduce dose of <span>rifabutin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span>plasma concentration of </span> <span>rifabutin</span> <span>reduced by</span> <span>efavirenz</span> <span>—increase dose of <span>rifabutin</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>possibly increased by</span> <span>erythromycin</span> <span>(increased risk of toxicity—reduce <span>rifabutin</span> dose)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td class="cAI"><p><span>plasma concentration of both drugs reduced when </span> <span>rifabutin</span> <span>given with</span> <span>etravirine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>fluconazole</span> <span>(increased risk of uveitis—reduce <span>rifabutin</span> dose)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>fosamprenavir</span> <span>(reduce dose of <span>rifabutin</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>indinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span></span> <span>rifabutin</span> <span>reduces plasma concentration of</span> <span>itraconazole</span> <span>—manufacturer of <span>itraconazole</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>avoidance of </span> <span>rifabutin</span> <span>advised by manufacturer of</span> <span>lapatinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>nelfinavir</span> <span>(halve dose of <span>rifabutin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td><p><span>plasma concentration of </span> <span>rifabutin</span> <span>possibly increased by</span> <span>nevirapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>posaconazole</span> <span>(also plasma concentration of <span>posaconazole</span> reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td class="cAI"><p><span></span> <span>rifabutin</span> <span>reduces plasma concentration of</span> <span>rilpivirine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of  </span> <span>rifabutin</span> <span>increased by</span> <span>ritonavir</span> <span>(increased risk of toxicity—reduce <span>rifabutin</span> dose)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>saquinavir</span> <span>(also plasma concentration of <span>saquinavir</span> reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span></span> <span>rifabutin</span> <span>reduces plasma concentration of</span> <span>sirolimus</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td><p><span></span> <span>rifabutin</span> <span>possibly reduces plasma concentration of</span> <span>tacrolimus</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>rifabutin</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>tipranavir</span> <span>(reduce dose of <span>rifabutin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1229-vemurafenib.htm">Vemurafenib</a></td><td><p><span>avoidance of </span> <span>rifabutin</span> <span>advised by manufacturer of</span> <span>vemurafenib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>rifabutin</span> <span>increased by</span> <span>voriconazole</span> <span>, also <span>rifabutin</span> reduces plasma concentration of <span>voriconazole</span> (increase dose of <span>voriconazole</span> and also monitor for <span>rifabutin</span> toxicity)</span>  </p></td><td></td></tr></tbody></table><p><strong>Rifampicin</strong> belongs to <strong>Rifamycins</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int907-abacavir.htm">Abacavir</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>abacavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int86-alfentanil.htm">Alfentanil</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>alfentanil</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1099-aliskiren.htm">Aliskiren</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>aliskiren</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span> <span>rifampicin</span> <span>reduced by</span> <span>antacids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>apixaban</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>aprepitant</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>aripiprazole</span> <span>—increase dose of <span>aripiprazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>atazanavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>atorvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int431-atovaquone.htm">Atovaquone</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>atovaquone</span> <span>(and concentration of rifampicin increased)—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int405-benzodiazepines.htm">Benzodiazepines</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly accelerates metabolism of</span> <span>benzodiazepines</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int443-bisoprolol.htm">Bisoprolol</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>bisoprolol</span> <span>(plasma concentration  significantly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>rifampicin</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span>(plasma concentration of <span>boceprevir</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int943-bosentan.htm">Bosentan</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>bosentan</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int427-buspirone.htm">Buspirone</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly accelerates metabolism of</span> <span>buspirone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span> <span>rifampicin</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int445-carvedilol.htm">Carvedilol</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>carvedilol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int947-caspofungin.htm">Caspofungin</a></td><td><p><span></span> <span>rifampicin</span> <span>initially increases and then reduces plasma concentration of</span> <span>caspofungin</span> <span>(consider increasing dose of <span>caspofungin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int898-celecoxib.htm">Celecoxib</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>celecoxib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int446-celiprolol.htm">Celiprolol</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>celiprolol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int158-chloramphenicol.htm">Chloramphenicol</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>chloramphenicol</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>ciclosporin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>cimetidine</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>clozapine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int88-codeine.htm">Codeine</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>codeine</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1120-dabigatran-etexilate.htm">Dabigatran Etexilate</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>dabigatran etexilate</span> <span>—manufacturer of <span>dabigatran etexilate</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>significantly reduces plasma concentration of</span> <span>darunavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1077-dasatinib.htm">Dasatinib</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>dasatinib</span> <span>(reduced plasma  concentration—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1072-deferasirox.htm">Deferasirox</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>deferasirox</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int412-diazepam.htm">Diazepam</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>diazepam</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int64-diclofenac.htm">Diclofenac</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>diclofenac</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>digoxin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int468-diltiazem.htm">Diltiazem</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>diltiazem</span> <span>(plasma concentration  significantly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int212-doxycycline.htm">Doxycycline</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>doxycycline</span> <span>—consider increasing dose of <span>doxycycline</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>dronedarone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>efavirenz</span> <span>—increase dose of <span>efavirenz</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>eplerenone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1205-eribulin.htm">Eribulin</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>eribulin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1048-erlotinib.htm">Erlotinib</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>erlotinib</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int960-etoricoxib.htm">Etoricoxib</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>etoricoxib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td><p><span>avoidance of </span> <span>rifampicin</span> <span>advised by manufacturer of</span> <span>etravirine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>everolimus</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1047-exemestane.htm">Exemestane</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>exemestane</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int95-fentanyl.htm">Fentanyl</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>fentanyl</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1119-fesoterodine.htm">Fesoterodine</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of active metabolite of</span> <span>fesoterodine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int308-fexofenadine.htm">Fexofenadine</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces effects of</span> <span>fexofenadine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>fluconazole</span> <span>(reduced plasma concentration)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int603-fluvastatin.htm">Fluvastatin</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>fluvastatin</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>significantly reduces plasma concentration of</span> <span>fosamprenavir</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int1170-gefitinib.htm">Gefitinib</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>gefitinib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>haloperidol</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int933-imatinib.htm">Imatinib</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>imatinib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int870-imidapril.htm">Imidapril</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of active metabolite of</span> <span>imidapril</span> <span>(reduced antihypertensive effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>indinavir</span> <span>(reduced plasma  concentration—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int472-isradipine.htm">Isradipine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>possibly accelerates metabolism of</span> <span>isradipine</span> <span>(possible significantly reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>itraconazole</span> <span>—manufacturer of <span>itraconazole</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>ketoconazole</span> <span>(reduced plasma concentration), also plasma concentration of <span>rifampicin</span> may be reduced by <span>ketoconazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int283-lamotrigine.htm">Lamotrigine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>lamotrigine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>avoidance of </span> <span>rifampicin</span> <span>advised by manufacturer of</span> <span>lapatinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int891-leflunomide.htm">Leflunomide</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly increases plasma concentration of active metabolite of</span> <span>leflunomide</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with other haematotoxic and hepatotoxic drugs</p></div></td></tr><tr><td><a href="bnf_int738-levothyroxine.htm">Levothyroxine</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>levothyroxine</span> <span>(may increase requirements for <span>levothyroxine</span> in hypothyroidism)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1210-linagliptin.htm">Linagliptin</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces effects of</span> <span>linagliptin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int917-linezolid.htm">Linezolid</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>linezolid</span> <span>(possible therapeutic failure of <span>linezolid</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Linezolid is a reversible, non-selective MAO inhibitor—see interactions of MAOIs</p></div></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>lopinavir</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as Kaletra® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int108-losartan.htm">Losartan</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>losartan</span> <span>and its active metabolite</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1107-maraviroc.htm">Maraviroc</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>maraviroc</span> <span>—consider increasing dose of <span>maraviroc</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int337-mefloquine.htm">Mefloquine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>mefloquine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>methadone</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int451-metoprolol.htm">Metoprolol</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>metoprolol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int98-morphine.htm">Morphine</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>morphine</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int520-mycophenolate.htm">Mycophenolate</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of active metabolite of</span> <span>mycophenolate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int920-nateglinide.htm">Nateglinide</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>nateglinide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>significantly reduces plasma concentration of</span> <span>nelfinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>nevirapine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int474-nicardipine.htm">Nicardipine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>possibly accelerates metabolism of</span> <span>nicardipine</span> <span>(possible significantly reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int475-nifedipine.htm">Nifedipine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>nifedipine</span> <span>(plasma concentration  significantly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1118-nilotinib.htm">Nilotinib</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>nilotinib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int476-nimodipine.htm">Nimodipine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>nimodipine</span> <span>(plasma concentration  significantly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1045-ondansetron.htm">Ondansetron</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>ondansetron</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int901-oxycodone.htm">Oxycodone</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly accelerates metabolism of</span> <span>oxycodone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1186-pazopanib.htm">Pazopanib</a></td><td class="cAI"><p><span>avoidance of </span> <span>rifampicin</span> <span>advised by manufacturer of</span> <span>pazopanib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span> <span>rifampicin</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1060-posaconazole.htm">Posaconazole</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>posaconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int125-propafenone.htm">Propafenone</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>propafenone</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int793-propranolol.htm">Propranolol</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>propranolol</span> <span>(plasma concentration  significantly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>quinine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1111-raltegravir.htm">Raltegravir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>raltegravir</span> <span>—consider increasing dose of <span>raltegravir</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>ranolazine</span> <span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int855-repaglinide.htm">Repaglinide</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly antagonises hypoglycaemic effect of</span> <span>repaglinide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1225-rilpivirine.htm">Rilpivirine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>rilpivirine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1136-rivaroxaban.htm">Rivaroxaban</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>rivaroxaban</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1190-roflumilast.htm">Roflumilast</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>roflumilast</span> <span>—consider increasing dose of <span>roflumilast</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>significantly reduces plasma concentration of</span> <span>saquinavir</span> <span>, also risk of hepatotoxicity—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>simvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>sirolimus</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1074-sorafenib.htm">Sorafenib</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>sorafenib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1075-sunitinib.htm">Sunitinib</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>sunitinib</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>tacrolimus</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int945-tadalafil.htm">Tadalafil</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>tadalafil</span> <span>—manufacturer of <span>tadalafil</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int581-tamoxifen.htm">Tamoxifen</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>tamoxifen</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>significantly reduces plasma concentration of</span> <span>telaprevir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>telithromycin</span> <span>(avoid during and for 2 weeks after <span>rifampicin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1137-temsirolimus.htm">Temsirolimus</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of active metabolite of</span> <span>temsirolimus</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> The main active metabolite of temsirolimus is sirolimus—see also interactions of sirolimus and consult product literature</p></div></td></tr><tr><td><a href="bnf_int292-terbinafine.htm">Terbinafine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>terbinafine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>theophylline</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int737-tibolone.htm">Tibolone</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>tibolone</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>ticagrelor</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>tipranavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1158-tolvaptan.htm">Tolvaptan</a></td><td><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>tolvaptan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int217-trimethoprim.htm">Trimethoprim</a></td><td><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>trimethoprim</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1163-ulipristal.htm">Ulipristal</a></td><td class="cAI"><p><span>avoidance of </span> <span>rifampicin</span> <span>advised by manufacturer of</span> <span>ulipristal</span> <span>(contraceptive effect of <span>ulipristal</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td><p><span>avoidance of </span> <span>rifampicin</span> <span>advised by manufacturer of</span> <span>vandetanib</span> <span>(plasma concentration of <span>vandetanib</span> reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1229-vemurafenib.htm">Vemurafenib</a></td><td><p><span>avoidance of </span> <span>rifampicin</span> <span>advised by manufacturer of</span> <span>vemurafenib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int467-verapamil.htm">Verapamil</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>verapamil</span> <span>(plasma concentration  significantly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1181-vinflunine.htm">Vinflunine</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>possibly reduces plasma concentration of</span> <span>vinflunine</span> <span>—manufacturer of <span>vinflunine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int948-voriconazole.htm">Voriconazole</a></td><td class="cAI"><p><span></span> <span>rifampicin</span> <span>reduces plasma concentration of</span> <span>voriconazole</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int904-zaleplon.htm">Zaleplon</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>zaleplon</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int403-zidovudine.htm">Zidovudine</a></td><td><p><span>avoidance of </span> <span>rifampicin</span> <span>advised by manufacturer of</span> <span>zidovudine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</p></div></td></tr><tr><td><a href="bnf_int425-zolpidem.htm">Zolpidem</a></td><td><p><span></span> <span>rifampicin</span> <span>accelerates metabolism of</span> <span>zolpidem</span> <span>(reduced plasma concentration and reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int426-zopiclone.htm">Zopiclone</a></td><td><p><span></span> <span>rifampicin</span> <span>significantly reduces plasma concentration of</span> <span>zopiclone</span> <span></span>  </p></td><td></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int200-rifabutin.htm" title="Rifabutin">Rifabutin</a></li><li><a href="bnf_int201-rifampicin.htm" title="Rifampicin">Rifampicin</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int198-ofloxacin.htm">Previous: Ofloxacin</a> | <a class="top" href="bnf_int199-rifamycins.htm#">Top</a> | <a accesskey="]" href="bnf_int200-rifabutin.htm">Next: Rifabutin</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>